<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636361</url>
  </required_header>
  <id_info>
    <org_study_id>16176</org_study_id>
    <secondary_id>I8B-FW-ITRJ</secondary_id>
    <nct_id>NCT02636361</nct_id>
  </id_info>
  <brief_title>A Study of Various Formulations of LY900014 in Healthy Participants</brief_title>
  <official_title>Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Multiple LY900014 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how quickly the body absorbs, breaks down, and gets rid of the
      different formulations of LY900014. This study will determine how the different formulations,
      when injected under the skin, will affect the blood sugar levels in the body, and how safe it
      is.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under The Concentration Curve (AUC) of LY900014</measure>
    <time_frame>Predose through 7 hours postdose in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp</measure>
    <time_frame>Predose through 5 hours postdose in each period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY900014 (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation A: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation B: Single dose of LY900014 formulation administered SC in one of five periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation C: Single dose of LY900014 formulation administered SC in one of five periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 (D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation D: Single dose of LY900014 formulation administered SC in one of five periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference formulation: Single dose of lispro administered SC in one of five periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered subcutaneously (SC)</description>
    <arm_group_label>LY900014 (A)</arm_group_label>
    <arm_group_label>LY900014 (B)</arm_group_label>
    <arm_group_label>LY900014 (C)</arm_group_label>
    <arm_group_label>LY900014 (D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy male or a female (not pregnant and agreeable to take birth control
             measures until one month after study completion)

          -  Must have a body mass index (BMI) of 18.0 to 30 kilogram per square meter (kg/mÂ²)
             (inclusive) at the time of study screening

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine
             laboratory test results that are acceptable for the study

          -  Are non-smokers or have not smoked for at least 2 months prior to entering the study,
             and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the
             duration of the study

          -  Have veins suitable for easy blood collection and glucose solution infusion

        Exclusion Criteria:

          -  Have known allergies to insulin lispro or compounds related to these drugs, or any
             components of the study drug

          -  Show signs of having an infection or infectious disease at the time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

